• FirefoxInstall the new Firefox »
  •  Dow Up0.86% Nasdaq Up0.90%

    Receptos, Inc. (RCPT)

    -NasdaqGS
    127.09 Up 0.45(0.36%) 4:00PM EST
    |After Hours : 127.07 Down 0.02 (0.02%) 6:38PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Receptos, Inc.
    10835 Road to the Cure
    Suite 205
    San Diego, CA 92121
    United States - Map
    Phone: 858-652-5700
    Fax: 858-587-2659
    Website: http://www.receptos.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:41

    Business Summary 

    Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics for immune disorders. Its lead product includes RPC1063, an oral sphingosine 1-phosphate 1 receptor modulator that is in Phase II portion of Phase II/III studies for the treatment of relapsing multiple sclerosis; and is in Phase II studies to treat ulcerative colitis. The company is also developing RPC4046, a monoclonal antibody, which is in Phase II studies for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that are in preclinical studies for the treatment of Type 2 diabetes. The company was formerly known as Receptor Pharmaceuticals, Inc. and changed its name to Receptos, Inc. in May 2009. Receptos, Inc. was founded in 2008 and is headquartered in San Diego, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Receptos, Inc.

    Corporate Governance 
    Receptos, Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 9. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 7; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. William H. Rastetter Ph.D., 67
    Co-Founder, Exec. Chairman, Chairman of Nominating & Corp. Governance Committee, Member of Audit Committee and Member of Compensation Committee
    52.00KN/A
    Mr. Faheem Hasnain , 57
    Chief Exec. Officer, Pres and Director
    804.00K0.00
    Ms. Kristina Burow , 42
    Co-Founder, Director, Chairman of Compensation Committee and Member of Nominating & Corp. Governance Committee
    34.00KN/A
    Mr. Graham K. Cooper , 45
    Chief Financial Officer and Principal Accounting Officer
    398.00K0.00
    Dr. Sheila Gujrathi M.D., 45
    Chief Medical officer
    524.00K0.00
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders